SCHEMBL1355901

SCHEMBL1355901

COC(=O)c1ccc(O)c(CCCc2cccc(N(C(C)C)C(C)C)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 5/20 0.47
CYP4F2 P78329 4/20 0.47
ALDH1A1 P00352 4/20 0.46
HPGD P15428 4/20 0.46
TP53 P04637 2/20 0.46
ALOX15 P16050 2/20 0.46
ALOX12 P18054 2/20 0.46
HSD17B10 Q99714 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CKS1B P61024 1/20 0.46
SKP2 Q13309 1/20 0.46
HIF1A Q16665 1/20 0.46
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA7 P43166 1/20 0.41
XDH P47989 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473875 0.88 GRIN2D (0.41) ALDH1A1ALOX15CYP1A2CYP3A4CYP2C19
SCHEMBL1901763 0.84 PTGER1 (0.47) CYP4A11CYP4F2HPGDMAPTSMN1; SMN2
SCHEMBL1355899 0.82 ALDH1A1 (0.46) CYP4A11CYP4F2ALDH1A1HPGDTP53
SCHEMBL7758292 0.81 SLC6A2 (0.42) CYP4A11CYP4F2ALDH1A1HPGDTP53
SCHEMBL3721174 0.80 IGF1R (0.39) ALOX15MAPTLMNAMEN1HTT
SCHEMBL11296010 0.80 ALDH1A1 (0.38) ALDH1A1HPGDTP53ALOX15ALOX12
SCHEMBL4190007 0.79 BACE1 (0.40) ALDH1A1ALOX15KDM4EMAPT
SCHEMBL722594 0.79 IGF1R (0.36) ALOX15
SCHEMBL2431823 0.79 CDK1 (0.35) ALDH1A1HPGDALOX15KDM4ERAB9A
SCHEMBL11300811 0.78 IGF1R (0.35) ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098560-A2 PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST MSN LABORATORIES LIMITED (IN) 2012-07-26 WO claimed
WO-2012098560-A2 PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST MSN LABORATORIES LIMITED (IN) 2012-07-26 WO disclosed
WO-2011158257-A1 PREPARATION PROCESS OF FESOTERODINE AND INTERMEDIATES PANACEA BIOTEC LTD (IN) 2011-12-22 WO disclosed
WO-2011141932-A2 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS INTAS PHARMACEUTICALS LIMITED (IN) 2011-11-17 WO disclosed
US-20110282094-A1 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS INTAS PHARMACEUTICALS LIMITED (IN) 2011-11-17 US disclosed
EP-1230209-B3 STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES UCB PHARMA GMBH (DE) 2011-10-05 EP disclosed
JP-2010180242-A STABLE SALT OF NOVEL DERIVATIVE OF 3,3-DIPHENYLPROPYLAMINES UCB PHARMA GMBH 2010-08-19 JP disclosed
JP-2007137895-A STABLE SALT OF NEW DERIVATIVE OF 3, 3-DIPHENYL PROPYLAMINES SCHWARZ PHARMA AG 2007-06-07 JP disclosed
US-6858650-B1 For therapy of urinary incontinence SCHWARZ PHARMA AG (DE) 2005-02-22 US disclosed
US-6858650-B1 For therapy of urinary incontinence SCHWARZ PHARMA AG (DE) 2005-02-22 US disclosed
EP-1230209-A2 STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2002-08-14 EP disclosed
WO-2001035957-A3 STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2001-12-27 WO disclosed
WO-2001035957-A8 STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2001-06-21 WO disclosed
WO-2001035957-A1 STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282094-A1 PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS HPD, COMT, PNMT CYP4A11 23/4885CYP4F2 67/4885ALDH1A1 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.